or Try an Advanced Search...

    Technical Analysis for MBRX - Moleculin Biotech, Inc.

    Grade Last Price % Change Price Change
    F 4.35 -5.43% -0.25
    MBRX closed down 5.43 percent on Wednesday, April 24, 2024, on 18 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 9
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical MBRX trend table...
    Date Alert Name Type % Chg
    180 Bearish Setup Bearish Swing Setup 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion -5.43%
    Oversold Stochastic Weakness -5.43%
    180 Bearish Setup Bearish Swing Setup 1.16%
    Outside Day Range Expansion 1.16%
    Wide Bands Range Expansion 1.16%
    Oversold Stochastic Weakness 1.16%
    Older End-of-Day Signals for MBRX ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Support about 14 hours ago
    60 Minute Opening Range Breakdown about 14 hours ago
    Down 3% about 14 hours ago
    Down 2 % about 14 hours ago
    Rose Above Previous Day's High about 15 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    MBRX Chart by TradingView
    Basic chart:

    Profile

    Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation of transcription factors involved in cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Pharmaceutical Oncology Acute Myeloid Leukemia Chemotherapy Antineoplastic Drugs Blastoma Glioblastoma Stage Pharmaceutical Transcription Transcription Factors Refractory Acute Myeloid Leukemia Transcription Factor Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia

    Is MBRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 18 Moleculin's acute myeloid leukemia treatment gets EMA's orphan drug designation
    Apr 18 European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
    Mar 28 Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
    Mar 27 Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
    Mar 27 Moleculin gets U.S. patent issue notification for annamycin targeting unmet need in AML
    Mar 27 Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
    Mar 26 Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript
    Mar 25 Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript
    Mar 25 Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
    Mar 22 Earnings Scheduled For March 22, 2024
    See more MBRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 15.75
    52 Week Low 4.28
    Average Volume 40,016
    200-Day Moving Average 8.04
    50-Day Moving Average 6.85
    20-Day Moving Average 4.93
    10-Day Moving Average 4.48
    Average True Range 0.57
    RSI (14) 35.06
    ADX 21.08
    +DI 22.52
    -DI 15.56
    Chandelier Exit (Long, 3 ATRs) 4.51
    Chandelier Exit (Short, 3 ATRs) 6.00
    Upper Bollinger Bands 5.92
    Lower Bollinger Band 3.94
    Percent B (%b) 0.21
    BandWidth 40.18
    MACD Line -0.70
    MACD Signal Line -0.78
    MACD Histogram 0.0769
    Fundamentals Value
    Market Cap 145.35 Million
    Num Shares 33.4 Million
    EPS -0.89
    Price-to-Earnings (P/E) Ratio -4.89
    Price-to-Sales 0.00
    Price-to-Book 0.48
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.76
    Resistance 3 (R3) 4.80 4.71 4.69
    Resistance 2 (R2) 4.71 4.61 4.69 4.67
    Resistance 1 (R1) 4.53 4.54 4.49 4.49 4.64
    Pivot Point 4.44 4.44 4.42 4.42 4.44
    Support 1 (S1) 4.26 4.34 4.21 4.21 4.06
    Support 2 (S2) 4.17 4.27 4.15 4.03
    Support 3 (S3) 3.99 4.17 4.01
    Support 4 (S4) 3.94